What is Oxurion?
Oxurion NV operates at the intersection of biotechnology and ophthalmology, dedicated to the development of novel medicines designed to combat vision loss. The company's core mission centers on addressing significant unmet medical needs, specifically targeting conditions such as geographic atrophy and age-related macular degeneration. By leveraging advanced scientific research, Oxurion aims to deliver transformative treatments that improve patient outcomes and quality of life. Its market position is defined by a rigorous focus on retinal health, positioning the firm as a specialized entity within the broader life sciences ecosystem.
How much funding has Oxurion raised?
Oxurion has raised a total of $154.4M across 4 funding rounds:
Private Equity
$95.5M
Other Financing Round
$21.7M
Debt
$2.2M
Other Financing Round
$35M
Private Equity (2022): $95.5M with participation from Negma Group
Other Financing Round (2023): $21.7M led by Atlas Special Opportunities
Debt (2023): $2.2M supported by Atlas Special Opportunities
Other Financing Round (2025): $35M featuring Atlas Special FX
Key Investors in Oxurion
Atlas Special FX
Atlas Special FX is a leading provider of special effects equipment rentals, including pyrotechnics and fog machines, catering to a diverse global clientele.
Negma Group
Negma Group is an investment firm that provides flexible financing solutions to growth-stage companies across various sectors.
Atlas Special Opportunities
Atlas Special Opportunities focuses on providing strategic capital and debt financing to support the growth and operational needs of emerging enterprises.
What's next for Oxurion?
With the successful closure of this latest financing round, Oxurion is well-positioned to advance its clinical development initiatives. The strategic allocation of these funds will likely prioritize the progression of its lead candidates through critical trial phases, ensuring that the company remains at the forefront of ophthalmic innovation. As the firm scales its operations, the focus will shift toward optimizing its therapeutic delivery mechanisms and strengthening its intellectual property portfolio. Investors and stakeholders will be closely monitoring the company's ability to translate this financial backing into tangible clinical results, which will be essential for long-term value creation in the competitive biopharmaceutical landscape.
See full Oxurion company page
